This site is intended for healthcare professionals
Drug news

New analysis of MYSTIC trial of Imfinzi monotherapy or Imfinzi + tremelimumab was presented at the ESMO Immuno-Oncology Congress- AstraZeneca

Read time: 1 mins
Last updated:20th Dec 2018
Published:20th Dec 2018
Source: Pharmawand

In a full analysis of the MYSTIC study of Imfinzi (durvalumab) monotherapy or Imfinzi + tremelimumab which was presented at the ESMO Immuno-Oncology 2018 congress in Geneva ,Naiyer Rizvi of the Columbia University Medical Center in New York who was study author, noted that while not reaching statistical significance, Imfinzi monotherapy gave a clinically meaningful median OS improvement of 16.3 months compared to 12.9 months with chemotherapy in patients with 25% or greater PD-L1 expression.

Moreover an exploratory analysis which examined survival according to the biomarker of high or low tumor mutational burden (TMB) in the blood � 16 or more mutations per megabase was defined as high and fewer than 16 as low. TMB evaluation was performed in more than 70% of patients, of whom 40% had high TMB and for those patients OS was 16.5 months with the Imfinzi/ tremelimumab combination versus 10.5 months with chemotherapy; OS with Imfinzi alone was 11 months.

The proportion of high TMB patients alive at two years was 39% with the combination, 30% with Imfinzi and 18% with chemotherapy, while in those with low TMB, OS was 8.5 months with Imfinzi plus tremelimumab, 12.2 months with Imfinzi and 11.6 months with chemotherapy.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.